Search results (8)
« Back to NewsR21 malaria vaccine phase III trial confirms high efficacy and safety
5 February 2024
The phase III trial data results of the R21/Matrix-M vaccine, developed by the Jenner Institute and the Serum Institute of India have confirmed high efficacy and supported regulatory approvals and licensure in several African countries.
Professor Sir Andrew Pollard reveals unique insights into the world of science in a new podcast
28 April 2023
Oxford Vaccine Group and Pandemic Sciences Institute’s Professor Pollard speaks to the people who shaped the COVID-19 pandemic in his new podcast, The Oxford Colloquy.
Therapeutic HIV vaccine with Oxford technology achieves encouraging results
4 November 2022
A phase I/IIa clinical trial that the University of Oxford collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was temporarily withdrawn.
Oxford vaccine saved most lives in its first year of rollout
15 July 2022
When the University of Oxford developed a vaccine that was effective against COVID-19, ensuring that it could be rolled out globally and in perpetuity for low- and middle-income countries was of paramount importance.
Oxford scientist named Australian of the Year in the UK
29 April 2022
The Oxford Vaccine Group’s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.
Oxford team to begin novel coronavirus vaccine research
7 February 2020
A research team at Oxford University’s Jenner Institute is preparing to begin clinical testing of a novel coronavirus vaccine candidate.
New MERS vaccine clinical trial starts in Saudi Arabia
20 December 2019
The King Abdullah International Medical Research Centre (KAIMRC), in collaboration with the University of Oxford’s Jenner Institute has started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).